Pathology: breast cancer - adjuvant; la/mBC - HR-positive - 2nd line (L2);
| breast cancer - adjuvant | la/mBC - HR-positive - 2nd line (L2) | |||
| Bachelot, 2022 | NCT02756364 (sapanisertib daily), 2022 | NCT02756364 (sapanisertib weekly), 2022 | ||
| sapanisertib plus fulvestrant | 2 | T1 | T1 | |
| everolimus | 1 | T1 | ||
| placebo | 0 | T0 | ||
| fulvestrant | 0 | T0 | T0 |